DGAP-News: Andera Partners to sell its Life Sciences' portfolio company ReViral to Pfizer
Retrieved on:
Tuesday, April 12, 2022
Therapy, Sale, Investment, Axon Sports, Growth, News, DGAP, Program, Death, CEO, Carbon, Immunodeficiency, Andera-ye Olya, Industry, Lists of publishing companies, Climate, RSV, Partner, Infection, Novo Nordisk, Partnership, Security (finance), Pharmaceutical industry, Vaccine, Fine chemical, Financial services, Pfizer, Vifor Pharma
Paris, April 7th, 2022 - Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences' portfolio company ReViral Ltd.
Key Points:
- Paris, April 7th, 2022 - Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences' portfolio company ReViral Ltd.
- Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally.
- Its teams manage over 3.2 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).
- Andera's 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital.